Cover Image

Clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age: an exploratory sub-analysis of the ABPARO trial

Aim The aim was to identify benefit thresholds for clinical variables. We hypothesize, if variables fall below or exceed these threshold levels, systemic amoxicillin/metronidazole may contribute to reducing progression of periodontitis. Material & Methods This is an explorative per-protocol coll...

Full description

Saved in:
Bibliographic Details
Main Authors: Eickholz, Peter (Author) , Koch, Raphael (Author) , Kocher, Thomas (Author) , Hoffmann, Thomas (Author) , Kim, Ti-Sun (Author) , Meyle, Jörg (Author) , Kaner, Doğan (Author) , Schlagenhauf, Ulrich (Author) , Harmsen, Dag (Author) , Harks, Inga (Author) , Ehmke, Benjamin (Author)
Format: Article (Journal)
Language:English
Published: 02 March 2019
In: Journal of clinical periodontology
Year: 2019, Volume: 46, Issue: 4, Pages: 491-501
ISSN:1600-051X
DOI:10.1111/jcpe.13096
Online Access:Verlag, Volltext: https://doi.org/10.1111/jcpe.13096
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpe.13096
Get full text
Author Notes:Peter Eickholz, Raphael Koch, Thomas Kocher, Thomas Hoffmann, Ti-Sun Kim, Joerg Meyle, Doğan Kaner, Ulrich Schlagenhauf, Dag Harmsen, Inga Harks, Benjamin Ehmke
Description
Summary:Aim The aim was to identify benefit thresholds for clinical variables. We hypothesize, if variables fall below or exceed these threshold levels, systemic amoxicillin/metronidazole may contribute to reducing progression of periodontitis. Material & Methods This is an explorative per-protocol collective analysis (n = 345) conducted on the placebo-controlled, multi-centre ABPARO trial (ClinicalTrials.gov NCT00707369). Patients received debridement with systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170) or placebo (n = 175) and maintenance therapy every three months. To identify thresholds, each of the following baseline characteristics was classified into two groups (≥threshold value/<threshold value): bleeding on probing, extent of pocket probing depth (PPD) ≥ 5 mm, mean clinical attachment level and age. Treatment effect (% of sites with new attachment loss ≥ 1.3 mm at 27.5 months post-treatment) was calculated. Results Adjunctive antimicrobials reduced median new attachment loss in patients < 55 years (5.2%), or with ≥ 35% PPD ≥ 5 mm (4.5%) or with a mean attachment level > 5 mm (5.2%) at baseline compared to the placebo (9.0%, 11.6%, and 12.5%, respectively; p < 0.005). Conclusions The clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age.
Item Description:Gesehen am 18.11.2019
Physical Description:Online Resource
ISSN:1600-051X
DOI:10.1111/jcpe.13096

Similar Items